Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Prothena Corporation plc

Market Cap 468M 408M 378M 353M 663M 44.11B 667M 4.48B 1.74B 21.71B 1.75B 1.72B 75.39B P/E 2026 *
191x
P/E 2027 * -8.67x
Enterprise Value 468M 408M 378M 353M 663M 44.11B 667M 4.48B 1.74B 21.71B 1.75B 1.72B 75.39B EV / Sales 2026 *
5.61x
EV / Sales 2027 * 21.3x
Free-Float
79.24%
Yield 2026 *
-
Yield 2027 * -
1 day+5.18%
1 week+8.24%
Current month-12.28%
1 month-1.54%
3 months+4.57%
6 months-3.04%
Current year-6.49%
1 week 7.85
Extreme 7.85
9.15
1 month 7.73
Extreme 7.73
10.26
Current year 7.73
Extreme 7.73
11.8
1 year 5.7
Extreme 5.7
11.8
3 years 4.32
Extreme 4.32
73.14
5 years 4.32
Extreme 4.32
79.75
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 2016-09-29
Director of Finance/CFO 52 2013-03-31
Chief Operating Officer 52 2021-09-28
Director TitleAgeSince
Chairman 76 2012-12-19
Director/Board Member 72 2012-12-19
Director/Board Member 63 2012-12-19
Date Insider Type Main position Quantity % Market Cap.
06-15Buy 20,000 0.0382%
06-14Don -325,000 0.6208%
06-10Buy 125,000 0.2388%
Change 5-day change 1-year change 3-year change Capi.($)
+5.18%+8.24%+55.30%-86.95% 468M
+1.44%-1.25%+63.52%+114.88% 55.19B
+4.60%+3.02%+58.20%+47.16% 45.75B
-1.44%+0.39%-12.94%-19.24% 22.98B
-2.69%-2.10%-3.68%+379.00% 20.76B
+3.22%-0.84%+27.88%-34.00% 16.26B
+0.58%+1.08%+16.73%-38.06% 15.42B
-1.01%-2.30%+27.42%+171.92% 13.05B
+4.95%+11.70%+123.63%+252.19% 12.45B
+3.07%+0.14%+29.37% - 12.37B
Average +1.79%+2.82%+38.54%+87.43% 21.47B
Weighted average by Cap. +1.64%+1.49%+40.95%+99.48%

Financials

2026 *2027 *
Net sales 83.32M 72.65M 67.28M 62.99M 118M 7.86B 119M 798M 309M 3.87B 313M 306M 13.44B 22M 19.18M 17.77M 16.63M 31.19M 2.08B 31.38M 211M 81.68M 1.02B 82.58M 80.81M 3.55B
Net income 2.42M 2.11M 1.96M 1.83M 3.44M 229M 3.46M 23.21M 9M 113M 9.1M 8.9M 391M -55.93M -48.76M -45.16M -42.28M -79.29M -5.28B -79.77M -536M -208M -2.6B -210M -205M -9.02B
Net Debt - -
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
26-06-18 8.930 $ +5.18% 1,390,843
26-06-17 8.490 $ +2.41% 542,968
26-06-16 8.290 $ +1.72% 586,273
26-06-15 8.150 $ -1.21% 622,611
26-06-12 8.250 $ -0.12% 315,405
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.930USD
Average target price
21.40USD
Spread / Average Target
+139.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTA Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!